Evelo Biosciences initiated with a Buy at Jefferies. Jefferies analyst Chris Howerton started Evelo Biosciences with a Buy rating and $18 price target. The analyst names Evelo his top pick for microbiome-based therapeutic approaches, given the company’s “strong platform and promising data to date.” With three assets in the clinic, 2019 and 2020 should be catalyst-rich years “promising significant value-creation,” Howerton tells investors in a research note.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.